Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18508
Country/Region: Kenya
Year: 2018
Main Partner: Centre for Health Solutions
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $9,107,493 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $506,028
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,796,134
Sexual Prevention: Other Sexual Prevention (HVOP) $500,035
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $625,155
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $5,115,579
Treatment: Pediatric Treatment (PDTX) $564,562
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 70
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 70
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 70
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 70
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 209
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 209
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 70
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 70
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 699
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 699
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 70
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 70
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 878
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 878
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 209
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 211
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 390
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 245
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 209
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 211
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 209
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 211
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 69
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 69
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 69
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 3,492
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 3,493
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 3,493
GEND_GBV Number of people receiving post-GBV care 2019 6,986
HTS_SELF 2019 13,634
HTS_SELF 15-19, Female, Directly-Assisted 2019 730
HTS_SELF 15-19, Female, Unassisted 2019 730
HTS_SELF 15-19, Male, Directly-Assisted 2019 244
HTS_SELF 15-19, Male, Unassisted 2019 244
HTS_SELF 20-24, Female, Directly-Assisted 2019 730
HTS_SELF 20-24, Female, Unassisted 2019 730
HTS_SELF 20-24, Male, Directly-Assisted 2019 244
HTS_SELF 20-24, Male, Unassisted 2019 244
HTS_SELF 25-29, Female, Directly-Assisted 2019 730
HTS_SELF 25-29, Female, Unassisted 2019 730
HTS_SELF 25-29, Male, Directly-Assisted 2019 244
HTS_SELF 25-29, Male, Unassisted 2019 244
HTS_SELF 30-34, Female, Directly-Assisted 2019 730
HTS_SELF 30-34, Female, Unassisted 2019 730
HTS_SELF 30-34, Male, Directly-Assisted 2019 243
HTS_SELF 30-34, Male, Unassisted 2019 243
HTS_SELF 35-39, Female, Directly-Assisted 2019 730
HTS_SELF 35-39, Female, Unassisted 2019 730
HTS_SELF 35-39, Male, Directly-Assisted 2019 244
HTS_SELF 35-39, Male, Unassisted 2019 244
HTS_SELF 40-49, Female, Directly-Assisted 2019 730
HTS_SELF 40-49, Female, Unassisted 2019 730
HTS_SELF 40-49, Male, Directly-Assisted 2019 244
HTS_SELF 40-49, Male, Unassisted 2019 244
HTS_SELF 50+, Female, Directly-Assisted 2019 730
HTS_SELF 50+, Female, Unassisted 2019 730
HTS_SELF 50+, Male, Directly-Assisted 2019 244
HTS_SELF 50+, Male, Unassisted 2019 244
HTS_SELF Directly-Assisted 2019 6,817
HTS_SELF FSW, Directly-Assisted 2019 9,133
HTS_SELF MSM, Directly-Assisted 2019 2,044
HTS_SELF PWID, Directly-Assisted 2019 535
HTS_SELF Unassisted 2019 6,817
HTS_SELF Unassisted - Other 2019 682
HTS_SELF Unassisted - Self 2019 3,408
HTS_SELF Unassisted - Sex Partner 2019 2,726
HTS_TST 15-19, Female, Negative 2019 336
HTS_TST 15-19, Male, Negative 2019 274
HTS_TST 20-24, Female, Negative 2019 1,177
HTS_TST 20-24, Male, Negative 2019 887
HTS_TST 25-29, Female, Negative 2019 488
HTS_TST 25-29, Female, Negative 2019 851
HTS_TST 25-29, Female, Negative 2019 34
HTS_TST 25-29, Female, Negative 2019 10,591
HTS_TST 25-29, Female, Negative 2019 7,342
HTS_TST 25-29, Female, Negative 2019 279
HTS_TST 25-29, Female, Negative 2019 128
HTS_TST 25-29, Female, Negative 2019 893
HTS_TST 25-29, Male, Negative 2019 136
HTS_TST 25-29, Male, Negative 2019 239
HTS_TST 25-29, Male, Negative 2019 2
HTS_TST 25-29, Male, Negative 2019 16,211
HTS_TST 25-29, Male, Negative 2019 76
HTS_TST 25-29, Male, Negative 2019 150
HTS_TST 25-29, Male, Negative 2019 157
HTS_TST 30-34, Female, Negative 2019 557
HTS_TST 30-34, Female, Negative 2019 973
HTS_TST 30-34, Female, Negative 2019 38
HTS_TST 30-34, Female, Negative 2019 11,709
HTS_TST 30-34, Female, Negative 2019 7,342
HTS_TST 30-34, Female, Negative 2019 317
HTS_TST 30-34, Female, Negative 2019 122
HTS_TST 30-34, Female, Negative 2019 1,020
HTS_TST 30-34, Male, Negative 2019 163
HTS_TST 30-34, Male, Negative 2019 288
HTS_TST 30-34, Male, Negative 2019 2
HTS_TST 30-34, Male, Negative 2019 19,266
HTS_TST 30-34, Male, Negative 2019 95
HTS_TST 30-34, Male, Negative 2019 189
HTS_TST 30-34, Male, Negative 2019 188
HTS_TST 35-39, Female, Negative 2019 140
HTS_TST 35-39, Female, Negative 2019 242
HTS_TST 35-39, Female, Negative 2019 9
HTS_TST 35-39, Female, Negative 2019 5,949
HTS_TST 35-39, Female, Negative 2019 7,342
HTS_TST 35-39, Female, Negative 2019 67
HTS_TST 35-39, Female, Negative 2019 140
HTS_TST 35-39, Female, Negative 2019 255
HTS_TST 35-39, Male, Negative 2019 163
HTS_TST 35-39, Male, Negative 2019 288
HTS_TST 35-39, Male, Negative 2019 2
HTS_TST 35-39, Male, Negative 2019 7,157
HTS_TST 35-39, Male, Negative 2019 95
HTS_TST 35-39, Male, Negative 2019 255
HTS_TST 35-39, Male, Negative 2019 188
HTS_TST 40-49, Female, Negative 2019 140
HTS_TST 40-49, Female, Negative 2019 242
HTS_TST 40-49, Female, Negative 2019 9
HTS_TST 40-49, Female, Negative 2019 5,949
HTS_TST 40-49, Female, Negative 2019 7,342
HTS_TST 40-49, Female, Negative 2019 67
HTS_TST 40-49, Female, Negative 2019 115
HTS_TST 40-49, Female, Negative 2019 255
HTS_TST 40-49, Male, Negative 2019 55
HTS_TST 40-49, Male, Negative 2019 97
HTS_TST 40-49, Male, Negative 2019 1
HTS_TST 40-49, Male, Negative 2019 2,386
HTS_TST 40-49, Male, Negative 2019 16
HTS_TST 40-49, Male, Negative 2019 263
HTS_TST 40-49, Male, Negative 2019 63
HTS_TST 50+, Female, Negative 2019 16
HTS_TST 50+, Male, Negative 2019 4
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 401,336
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 51
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 35
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 175
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 112
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 143
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 7,516
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 20,322
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 761
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 219
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,391
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 338
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 449
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 593
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 478
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 2,045
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,978
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 69
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 27
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 20
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 119
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 39
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1,029
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 829
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 3,550
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 2,653
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 123
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 48
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 3,721
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 691
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 1,178
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 16,626
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 28,577
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 86,107
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 64,648
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 2,976
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,192
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 8,407
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 67
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 83
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 81
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 143
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 186
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 153
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 190
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 109
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 209
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 2
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 1,234
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 919
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 4,252
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 2,938
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 127
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 31
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 599
HTS_TST_POS 15-19, Male, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 121
HTS_TST_POS 25-29, Female, Positive 2019 12
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 194
HTS_TST_POS 25-29, Female, Positive 2019 654
HTS_TST_POS 25-29, Female, Positive 2019 28
HTS_TST_POS 25-29, Female, Positive 2019 18
HTS_TST_POS 25-29, Male, Positive 2019 36
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 25-29, Male, Positive 2019 294
HTS_TST_POS 25-29, Male, Positive 2019 29
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 138
HTS_TST_POS 30-34, Female, Positive 2019 15
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 215
HTS_TST_POS 30-34, Female, Positive 2019 21
HTS_TST_POS 30-34, Female, Positive 2019 20
HTS_TST_POS 30-34, Male, Positive 2019 41
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 30-34, Male, Positive 2019 367
HTS_TST_POS 30-34, Male, Positive 2019 35
HTS_TST_POS 30-34, Male, Positive 2019 5
HTS_TST_POS 35-39, Female, Positive 2019 35
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 95
HTS_TST_POS 35-39, Female, Positive 2019 29
HTS_TST_POS 35-39, Female, Positive 2019 5
HTS_TST_POS 35-39, Male, Positive 2019 41
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 129
HTS_TST_POS 35-39, Male, Positive 2019 64
HTS_TST_POS 35-39, Male, Positive 2019 5
HTS_TST_POS 40-49, Female, Positive 2019 35
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 95
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Female, Positive 2019 5
HTS_TST_POS 40-49, Male, Positive 2019 14
HTS_TST_POS 40-49, Male, Positive 2019 30
HTS_TST_POS 40-49, Male, Positive 2019 58
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 263
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 144
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 117
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 480
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 392
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 63
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 49
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 317
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 553
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1,636
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 1,243
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 28
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 78
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 57
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 1
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 4,615
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 228
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 254
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 9
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,890
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 6,996
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,316
PMTCT_ART New on ART 2019 941
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,257
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 62,979
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 324
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 324
PMTCT_EID Sum of Infant Age disaggregates 2019 324
PMTCT_STAT 25-29, Female 2019 8,026
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 278
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 7,639
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 109
PMTCT_STAT 30-34, Female 2019 8,002
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 278
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 7,615
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 109
PMTCT_STAT 35-39, Female 2019 8,002
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 278
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 7,615
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 109
PMTCT_STAT 40-49, Female 2019 8,026
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 278
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 7,639
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 109
PMTCT_STAT By Age (Numerator): 10-14 2019 148
PMTCT_STAT By Age (Numerator): 15-19 2019 8,126
PMTCT_STAT By Age (Numerator): 20-24 2019 21,821
PMTCT_STAT By Age (Numerator): 50+ 2019 828
PMTCT_STAT By Number of known positives: 15-19 2019 59
PMTCT_STAT By Number of known positives: 20-24 2019 276
PMTCT_STAT By Number of new negative: 10-14 2019 146
PMTCT_STAT By Number of new negative: 15-19 2019 7,937
PMTCT_STAT By Number of new negative: 20-24 2019 21,202
PMTCT_STAT By Number of new negative: 50+ 2019 816
PMTCT_STAT By Number of new positives: 10-14 2019 2
PMTCT_STAT By Number of new positives: 15-19 2019 130
PMTCT_STAT By Number of new positives: 20-24 2019 343
PMTCT_STAT By Number of new positives: 50+ 2019 12
PMTCT_STAT Number of new ANC and L&D clients 2019 65,473
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 62,979
PMTCT_STAT_den 25-29, Female 2019 8,056
PMTCT_STAT_den 30-34, Female 2019 8,056
PMTCT_STAT_den 35-39, Female 2019 8,056
PMTCT_STAT_den 40-49, Female 2019 8,056
PMTCT_STAT_den By Age (Denominator): <15-19 2019 9,129
PMTCT_STAT_den By Age (Denominator): 10-14 2019 118
PMTCT_STAT_den By Age (Denominator): 20-24 2019 22,073
PMTCT_STAT_den By Age (Denominator): 50+ 2019 1,929
PP_PREV 25-29, Female 2019 9
PP_PREV 25-29, Male 2019 731
PP_PREV 30-34, Female 2019 9
PP_PREV 30-34, Male 2019 731
PP_PREV 35-39, Female 2019 9
PP_PREV 35-39, Male 2019 731
PP_PREV 40-49, Female 2019 9
PP_PREV 40-49, Male 2019 731
PP_PREV Age/sex: 10-14 Female 2019 188
PP_PREV Age/sex: 10-14 Male 2019 58
PP_PREV Age/sex: 15-19 Female 2019 36
PP_PREV Age/sex: 15-19 Male 2019 863
PP_PREV Age/sex: 20-24 Female 2019 14
PP_PREV Age/sex: 20-24 Male 2019 1,914
PP_PREV Age/sex: 50+ Female 2019 2
PP_PREV Age/sex: 50+ Male 2019 465
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 6,500
PP_PREV Sum of Age/Sex disaggregates 2019 3,540
PrEP_NEW 25-29, Female 2019 83
PrEP_NEW 25-29, Male 2019 36
PrEP_NEW 30-34, Female 2019 59
PrEP_NEW 30-34, Male 2019 47
PrEP_NEW 35-39, Female 2019 59
PrEP_NEW 35-39, Male 2019 47
PrEP_NEW 40-49, Female 2019 59
PrEP_NEW 40-49, Male 2019 36
PrEP_NEW Female 15-19 2019 139
PrEP_NEW Female 20-24 2019 469
PrEP_NEW Female 50+ 2019 24
PrEP_NEW FSW 2019 166
PrEP_NEW Male 15-19 2019 13
PrEP_NEW Male 20-24 2019 71
PrEP_NEW Male 50+ 2019 24
PrEP_NEW MSM 2019 83
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,166
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 416
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 589
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 1,005
TB_PREV By Age/Sex (Numerator): <15, Female 2019 582
TB_PREV By Age/Sex (Numerator): <15, Male 2019 556
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 4,946
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,821
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 7,905
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 9,267
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 666
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 633
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 5,840
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 2,128
TB_PREV_den IPT, Life-long ART, New, Positive 2019 9,267
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 116
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,199
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 100
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 2,766
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 4,181
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 4,181
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 116
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,192
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 104
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 2,769
TX_CURR 25-29, Female, Positive 2019 9,813
TX_CURR 25-29, Male, Positive 2019 1,717
TX_CURR 30-34, Female, Positive 2019 7,438
TX_CURR 30-34, Male, Positive 2019 2,703
TX_CURR 35-39, Female, Positive 2019 7,387
TX_CURR 35-39, Male, Positive 2019 2,679
TX_CURR 40-49, Female, Positive 2019 5,052
TX_CURR 40-49, Male, Positive 2019 2,679
TX_CURR Age/Sex: <1 2019 31
TX_CURR Age/Sex: <1-9 2019 2,577
TX_CURR Age/Sex: 10-14 Female 2019 1,388
TX_CURR Age/Sex: 10-14 Male 2019 1,362
TX_CURR Age/Sex: 15-19 Female 2019 1,892
TX_CURR Age/Sex: 15-19 Male 2019 1,026
TX_CURR Age/Sex: 20-24 Female 2019 5,264
TX_CURR Age/Sex: 20-24 Male 2019 1,370
TX_CURR Age/Sex: 50+ Female 2019 4,038
TX_CURR Age/Sex: 50+ Male 2019 965
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 59,381
TX_CURR Sum of age/sex disaggregates 2019 2,918
TX_NEW 25-29, Female, Positive 2019 658
TX_NEW 25-29, Male, Positive 2019 177
TX_NEW 30-34, Female, Positive 2019 725
TX_NEW 30-34, Male, Positive 2019 211
TX_NEW 35-39, Female, Positive 2019 182
TX_NEW 35-39, Male, Positive 2019 211
TX_NEW 40-49, Female, Positive 2019 182
TX_NEW 40-49, Male, Positive 2019 63
TX_NEW Breastfeeding status 2019 68
TX_NEW By Age/Sex: <1 2019 139
TX_NEW By Age/Sex: 1-9 2019 81
TX_NEW By Age/Sex: 10-14 Female 2019 15
TX_NEW By Age/Sex: 10-14 Male 2019 28
TX_NEW By Age/Sex: 15-19 Female 2019 792
TX_NEW By Age/Sex: 15-19 Male 2019 640
TX_NEW By Age/Sex: 20-24 Female 2019 2,818
TX_NEW By Age/Sex: 20-24 Male 2019 2,060
TX_NEW By Age/Sex: 50+ Female 2019 97
TX_NEW By Age/Sex: 50+ Male 2019 39
TX_NEW FSW 2019 169
TX_NEW MSM 2019 18
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 9,118
TX_NEW People in prisons and other enclosed settings 2019 33
TX_NEW Pregnancy status 2019 677
TX_NEW Sum of Age/Sex disaggregates 2019 6,489
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 57,824
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,310
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 2,310
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 31,811
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 21,393
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 9,128
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4,451
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 13,579
TX_RET Numerator by Status: Breastfeeding 2019 2
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 15,138
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 9,990
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 4,593
TX_RET_den Denominator by Status: Breastfeeding 2019 2
TX_RET_den Denominator by Status: Pregnant 2019 22
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 59,409
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 2,981
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 2,912
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 38,843
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 14,673
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 2,177
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 60
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 2,229
Cross Cutting Budget Categories and Known Amounts Total: $1,912,685
Gender: Gender Based Violence (GBV) $158,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $1,332,029
Motor Vehicles: Purchased $178,812
Renovation $243,844